Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent injections compared with standard FVIII products. This phase III (NCT01480180), multinational, open-label, non-randomised trial evaluated the safety and clinical efficacy of N8-GP when administered for treatment of bleeds and for prophylaxis, in previously treated patients aged ≥12 years with severe haemophilia A. Patients were allocated to receive N8-GP for prophylaxis or on-demand treatment for up to 1.8 years. Patients on prophylaxis were administered one dose of 50 IU/kg of N8-GP every fourth day. Bleeds were treated with doses of 20-75 IU/kg. Total exposure to N8-GP in the trial was 14,114 exposure days (159 patient-years). For the prophylaxis arm (n=175), the median annualised bleeding rate (ABR) was 1.33 (interquartile range, 0.00-4.61), the mean ABR was 3.70 (95 % confidence interval 2.94-4.66) and 70 (40 %) patients had no bleeds during the trial. Across treatment arms, 83.6 % of bleeds resolved with one injection and 95.5 % with up to two injections. N8-GP had a favourable safety profile and was well tolerated. The frequency and types of adverse events reported were as expected in this population. One patient developed inhibitory antibodies against FVIII (≥0.6 Bethesda units [BU]) after 93 N8-GP exposure days. No clinically significant safety concerns were identified and N8-GP was effective for prophylaxis and treatment of bleeds in previously treated patients.
Background
Mast cell activation syndrome (MCAS), a recently recognized non-neoplastic mast cell (MC) disease driving chronic multisystem inflammation ± allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population.
Method
Demographics, comorbidities, symptoms, family histories, and physical exam and laboratory findings were reviewed in 298 retrospective and 115 prospective MCAS patients. Blood samples from prospective subjects were examined by flow cytometry for clonal MC disease and tested for cytokines potentially driving the monocytosis frequent in MCAS.
Results
Demographically, white females dominated. Median ages at symptom onset/diagnosis were 9/49 years (ranges 0–88/16–92); median time from symptom onset to diagnosis was 30 years (range 1–85). Median numbers of comorbidities/symptoms/family medical issues were 11/20/4 (ranges 1–66/2–84/0–33). Gastroesophageal reflux, fatigue, and dermatographism were the most common comorbidity, symptom, and exam finding. Abnormalities in routine labs were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D2, histamine, and chromogranin A. Flow cytometric and cytokine assessments were unhelpful.
Conclusions
Our study highlights MCAS’s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects.
Patients presenting with refractory anemia and leukopenia with or without associated neurologic deficits should have copper and ceruloplasmin levels measured as part of their diagnostic evaluation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.